My 2 Favorite Dividend Kings to Buy Right Now

The immediate market read is not “buy healthcare,” but “buy cash-flow visibility when macro tape is noisy.” That tends to support ABBV and JNJ as relative winners in a risk-off rotation, but the alpha is likely in factor spread, not absolute upside: if geopolitics cools, the bid can fade quickly. The more interesting second-order effect is that these names may attract defensive inflows from investors de-risking out of rate-sensitive dividend proxies, which can compress dispersion within XLV rather than lift the whole complex.

ABBV has more torque than the headline implies because the market is paying for durability while underappreciating how much of the next 12-18 months depends on pipeline execution and M&A integration, not the dividend. JNJ is the cleaner ballast, but that stability comes with lower convexity: once the “safe harbor” premium is fully priced, upside likely stalls unless new device/regulatory catalysts reaccelerate growth. APGE mainly matters as an option on future immunology breadth; near-term, deal premium capture is probably already the cleaner expression than owning ABBV for the acquisition alone.

Contrarian view: the consensus may be overpaying for defensiveness just as healthcare becomes a crowded hideout trade. If the Middle East headline risk proves transient, high-yield healthcare can underperform on a 1-3 month horizon as investors rotate back to cyclicals and AI/semis; the quality premium is not free. Falsifiers are straightforward: a meaningful reset lower in war-risk headlines, or—on the stock-specific side—any sign that ABBV’s growth pillars are slowing faster than pipeline assets can refill them, and for JNJ a regulatory delay on Ottava or renewed litigation overhangs that negate the “all-weather” narrative.